Oncolytic virotherapy -<i>in vivo veritas</i>

Kemler, Iris; Neuhauser, Claudia; Dingli, David

doi:10.18632/oncotarget.26364

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the resolution provided by micro-SPECT/CT is not enough to allow proper quantification of the size of the infected tumor foci [79] and imaging techniques with a higher resolution are needed. This is clearly an example where the average is not good enough since significant across animals and between metastatic tumor deposits within the same animal can be expected due to spatial anisotropies and stochastic effects with respect to both the tumor cells and the sites of tumor cell infection by the virus [77,79,80,91]. It is likely that accurate determination of the number of tumor cells, how many of them are infected, and the spatial distribution of infected cells within the tumor environment is required for better understanding of isotope-based imaging data.…”

Section: And (B) Anisotropies In the Distribution Of The Virusmentioning

confidence: 99%

Quantitative imaging and dynamics of tumor therapy with viruses

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cancer therapy remains challenging due to the myriad presentations of the disease and the vast genetic diversity of tumors that continuously evolve and often become resistant to therapy. Viruses can be engineered to specifically infect, replicate, and kill tumor cells (tumor virotherapy). Moreover, the viruses can be 'armed' with therapeutic genes to enhance their oncolytic effect. Using viruses to treat cancer is exciting and novel and in principle can be used for a broad variety of tumors. However, the approach is distinctly different from other cancer therapies since success depends on establishment of an infection within the tumor and ongoing propagation of the oncolytic virus within the tumor itself. Therefore, the target itself amplifies the therapy. This introduces complex dynamics especially when the immune system is taken into consideration as well as the physical and other biological barriers to virus growth. Understanding these dynamics not only requires mathematical and computational models but also approaches for the non-invasive monitoring of the virus and tumor populations. In this perspective, we discuss strategies and current results to achieve this important goal of understanding these dynamics in pursuit of optimization of oncolytic virotherapy.

show abstract